New indication for Olumiant (baricitinib) as oral treatment for moderate to severe atopic dermatitis
18 Settembre 2020
EMA has recommended granting an extension of indication to Olumiant (baricitinib) to include the treatment of moderate to severe atopic dermatitis in adult patients who are candidates
